Peter Tobin PhD, MBA

Dr Peter Tobin is the Associate Medical Director and Head of Oncology for Medical Affairs at Merck. Peter has worked in the pharmaceutical industry for over 11 years in a variety of roles including communications, market access, and medical affairs. He has worked on bringing new medicines to people living with cancer in Australia and New Zealand including docetaxel, cabazitaxel, aflibercept, everolimus, imatinib, octreotide LAR, ribociclib, cetuximab, and more recently avelumab. He has been the country medical lead on early access and compassionate supply programs, national and international medical education events, advisory boards, and company-sponsored and investigator-initiated studies.
He studied biochemistry and pharmacology at the University of Sydney and was awarded the University Medal and first-class honours. He then completed a Doctor of Philosophy (Medicine) at the University of Sydney. His thesis focussed on how a better understanding of the metabolism of irinotecan could improve its tolerability profile in patients with metastatic colorectal cancer. He has published preclinical and clinical research arising from these studies and served as a reviewer for peer-reviewed journals. He is currently completing a Masters of Business Administration at the Macquarie Graduate School of Management.